SEATTLE and RICHMOND, BRITISH COLUMBIA - August 26, 2026 (NEWMEDIAWIRE) - Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement covering Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies. Under the terms of the agreement, SignalChem Biotech may incorporate these technologies into custom luminescent assay development and protein-fusion services offered to third-party customers for research use. This collaboration expands SignalChem's specialized CRO capabilities and supports Sino Biological's broader strategy of incorporating AI-enabled technologies across its global life science tools and services portfolio.
The significance of this announcement lies in the growing integration of AI-designed proteins into commercial research services. Monod Bio's LuxSit luciferase is engineered for use in robust luminescent biosensors, while NovoBodies are compact, highly stable binding proteins designed for high-performance recognition of various targets. Together, these technologies provide versatile tools for developing customized assays and discovery workflows. By licensing these technologies, SignalChem Biotech can offer enhanced custom assay services that leverage AI-driven protein design, potentially accelerating drug discovery and life science research for its customers.
Dr. Rob Burgess, Chief Business Officer of Sino Biological, stated, "By incorporating Monod Bio's AI-designed protein technologies into SignalChem's custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly. This agreement and the corresponding licensed technology strengthen our ability to help customers address complex biological questions and advance their research programs more efficiently." This partnership reflects a strategic move by Sino Biological to stay at the forefront of technological innovation in the life science tools industry.
Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio, added, "SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services." The Monod Inside model is a key aspect of Monod Bio's business strategy, allowing other companies to integrate its technologies into their offerings.
The licensing agreement is non-exclusive, meaning Monod Bio retains the ability to license its technologies to other partners. This approach could foster wider adoption of AI-designed proteins across the industry. For SignalChem Biotech, the incorporation of LuxSit and NovoBodies into its custom assay services will enhance its ability to provide specialized solutions to its clients, potentially improving the efficiency and effectiveness of research programs.
This collaboration is part of a broader trend where AI is being used to design novel proteins with specific functions, which can then be commercialized for research and diagnostic applications. Monod Bio's expertise in AI-powered de novo protein design positions it as a leader in this space, and partnerships like this one are crucial for translating cutting-edge research into practical tools that benefit the scientific community.
For more information about Sino Biological, visit www.sinobiological.com. For more information about Monod Bio, visit monod.bio.
